<DOC>
	<DOCNO>NCT02176265</DOCNO>
	<brief_summary>Objective First Man study assess feasibility safety Qvanteq 's bioactive coronary stent treatment stable coronary artery disease patient de novo coronary artery stenosis native vessel . The proprietary surface Qvanteq 's bioactive coronary stent improve in-growth behavior stent treat vessel . In-vivo animal study reveal fast in-growth ( similar BMS ) , however result excessive tissue overgrowth observe BMS rather efficacy profile similar drug-eluting stent ( DES ) , mean suppression tissue overgrowth . This reduce risk restenosis thrombus formation despite presence short term dual anti platelet therapy ( DAPT ) . Furthermore , prolonged DAPT time apply current DES increase bleed risk patient . The study prospective , multicenter , open-label , single arm study ; conduct 6 cardiology center CH NL . In total , approx . 35 patient enrol . All patient treat Qvanteq 's bioactive coronary stent . Clinical follow-up occur 1 , 6 &amp; 12 month post-stent implantation . All patient undergo angiography assessment ( QCA ) Optical Coherence Tomography investigation ( OCT ) baseline 6 month follow-up . Baseline OCT perform successfully complete angiographic procedure ( documentary OCT ) . 1 12 month clinical follow-up conduct via telephone . Primary Angiographic endpoint in-stent Late Lumen Loss 6 month ; assess off-line QCA . Primary OCT endpoint mean neointimal thickness 6 month ; assess off-line OCT analysis .</brief_summary>
	<brief_title>Qvanteq Bioactive Coronary Stent System First Man ( FIM ) Clinical Investigation</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Subjects must least 18 year age Evidence myocardial ischemia without elevated cardiac biomarkers ( e.g . stable unstable angina stable haemodynamic condition , silent ischemia demonstrate positive territorial functional study ) The patient plan intervention one single de novo lesion one two separate major epicardial territory ( LAD , LCX , RCA ) . The lesion must visually estimate diameter stenosis ≥ 50 % &lt; 100 % Lesion length must ≤16 mm The vessel size must 2.5 3.5 mm Written inform consent The patient agree followup visit include angiographic followup OCT control 6 month Key Evidence ongoing acute myocardial infarction ( AMI ) ECG and/or elevate cardiac biomarkers ( accord local standard hospital practice ) return within normal limit time procedure . Patient suffer stroke/TIA myocardial infarction last 6 month LVEF &lt; 30 % Platelet count &lt; 100,000 cells/mm3 &gt; 400,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) Known renal insufficiency ( Creatinine clearance le 30 mL/Min ) , subject dialysis , acute kidney failure Patient undergoing plan surgery within 6 month necessity stop ASA Patient require prolonged DAPT diagnosis ( &gt; 1 month ) History bleed diathesis coagulopathy Patient require oral anticoagulation ( Coumadin , NOAC ) The patient recipient heart transplant Known hypersensitivity contraindication aspirin , heparin , clopidogrel cobaltchromium Other medical illness ( e.g . cancer , stroke neurological deficiency ) know history substance abuse ( alcohol , cocaine , heroin etc . ) per physician judgment may cause noncompliance protocol confound data interpretation associate limited life expectancy Female child bear potential ( age &lt; 50 year last menstruation within last 12 month ) , underwent tubal ligation , ovariectomy hysterectomy . Previous CABG Angiographic Severe tortuous , calcify angulated coronary anatomy study vessel opinion investigator would result suboptimal image excessive risk complication placement OCT catheter Target lesion leave main stem . Target lesion involve side branch &gt; 2.0mm diameter Aortoostial target lesion ( within 3 mm aorta junction ) . Total occlusion TIMI flow &lt; 3 , prior wire cross The target vessel contain visible thrombus Restenotic lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CAD</keyword>
	<keyword>PCI</keyword>
	<keyword>bioactive coronary stent</keyword>
	<keyword>OCT</keyword>
</DOC>